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RESEARCH ARTICLE
Our experience of Mega-prosthesis in bone tumours: A retrospective
cross-sectional study in a tertiary care hospital
Masood Umer, Eraj Khurshid Khan, Javeria Saeed

Abstract
Objective: To evaluate the oncological and functional outcomes of bone tumour patients who underwent
reconstruction with mega prosthesis.
Methodology: A retrospective study was conducted in the department of Orthopaedics Aga Khan University
Hospital, Karachi. All the paediatric and adult age group patients diagnosed with malignant, benign and metastatic
bone tumours and meeting the inclusion criteria were selected and analysed. Retrospective data was collected from
January 2008-January 2018.
Result: Sixty-two patients, 30 (48.4%) females and 32 (51.6%) males. were included in the study. Of these 57 (92%)
cases had involvement of the lower limb. The mean age was 36.95±19.1 years with a range of 9-81 years. The
duration of patients follow up was from 1-124 months (mean 32.7±36.43 months). There were 29 (47%) malignant
cases. The most commonly occurring tumour site was distal femur and proximal femur. There were 53 (85%) primary
surgeries (first time conducted surgeries) while 9(15%) revision surgeries were done. Major complications were
encountered in 19 (30.6%) patients and 13 (20.9%) had minor complications. Post-surgery local recurrence occurred
in 2 (3.2%) patients while 7 (11.2%) had distant metastasis. In functional outcomes the mean MSTS score of our
patients was 72.09±26.43. The survival rate was 69.8% with 45 patients recovered.
Conclusion: With a good patient selection, adherence to the principles of tumour surgery and an adequate applied
knowledge of mega prosthesis insertion, a good functional outcome was achieved.
Keywords: Bone neoplasm, Lower extremity, Femur, Recurrence. (JPMA 71: S-45 [Suppl. 5]; 2021)

Introduction
Since the introduction of first endoprosthesis in 1943 by
Austin Moore, made of Vitallium (Chromium Cobalt Alloy),
and the description of Total Femur Replacement by
Buchanan in 1950, there had been a significant change in
the management of extremity bone tumours in favour of
limb salvage surgery.1,2 The introduction of
chemotherapy particularly neo-adjuvant chemotherapy,
the advances in surgical and diagnostic techniques, and
the multidisciplinary approach allowed limb salvage
procedures for sarcoma, with no obvious detectable
differences in oncologic or functional results when
compared with amputation.3,4 Hence, since 1980s, mega
prosthesis had become the cornerstone of limb salvage
surgeries, owing to their facilitation in early return to
function, ability to bear weight, easy availability and
better cosmetic appearance. Their use, in general, has
drastically increased since the introduction of off-theshelf modular prosthesis instead of previously used
custom prosthesis. It is due to all of these factors that the
limb salvage surgery is now indicated in up to 90% of the
musculoskeletal tumours.4
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In the light of these factors, there had been an evolution
over the past three decades, in the biomedical
engineering and refinement of surgical technique to
enhance the oncological and functional outcome of
endoprosthesis replacement which has, since then,
become the primary modality of choice for limb salvage
surgery.4,5 However, in the developing world, cost has
been the most decisive limitation in the use of these
implants. In a country where public has to pay for these
services from their own resources, it becomes an
expensive and unaffordable modality of choice and thus,
presents a different kind of challenge.5 This is further
aggravated by the non-availability of allograft in the
country and absence of a bone bank. We are presenting
our experience with functional outcome of mega endoprosthetic replacement over the past decade. A previous
study was carried out by us in 2012, which has been the
only work on mega-prosthetic replacement in Pakistan to
this date.5

Methods
A retrospective study was conducted in the Aga Khan
University Hospital, department. of Orthopaedics after
ERC approval. All the patients diagnosed with malignant,
benign and metastatic bone tumours were included. All
paediatric and adult age group patients were considered
Vol. 71, No. 8 (Suppl. 5), August 2021
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eligible for inclusion in the study. The medical records of
patients from January 2008 to January 2018 were
reviewed and the follow-up was taken till October 2018.
There were 58 patients who were included in study. For
assessing functional outcomes in treated patients,
Musculoskeletal Tumour Society (MSTS) scoring system
was used. This system assigns numerical values (0-5) for
each of six categories: pain, and function and emotional
acceptance in the upper and lower extremities; supports,
and walking and gait in the lower extremity; and hand
positioning, and dexterity and lifting ability in the upper
extremity.6 These values were added, and the functional
score was presented as a percentage of the maximum
possible score. The results were graded according to the
following scale: excellent 75-100%; good 70-74%;
moderate 60-69%; fair 50-59 %; and poor 50 % based on
our previous study.2 Post-surgery complications and
patient's status either with local disease or metastatic
disease were noted. Data was analyzed on statistical
software SPSS version 22. Frequencies and descriptive
statistic were calculated for categorical quantitative
variables respectively. Chi2- Test was run for analyzing
associations among variables and P-value < 0.05 was
considered as significant for finding associations among
variables. Kaplan-Meier test was used for calculating
survival status of patients.

Results

Table-1: Management of post-surgery complications.
Variables
Non Operative
Open/Closed Reduction
Wound Debridement
Wound Debridement + Flap Coverage
Revision
Amputation
Others

No. of Patients

Percentage

13
6
2
4
3
3
2

21
9.6
3.2
6.4
4.8
4.8
3.2

arthroplasty, and 5(8%) had total femur replacement
while 5 underwent proximal humerus replacement.
Regarding oncological outcome, margins were negative
in all primary bone tumours. Two patients had local
recurrence while 7 had distant metastasis. Four patients
were lost to follow up, however, they remained disease
free till their last documented follow up.
MSTS functional score was assessed in 34 patients, which
gave a mean score of 72.09±26.43 (Range 27-100).
Excellent outcome was achieved in 18, good outcome in
6, fair in 5 while poor outcome was reported in 6 cases.
There was an inverse relationship between age and MSTS
score which was significant with p<0.01. No significant
difference was found in the functional score of hip and
knee surgery patients or secondary to difference in
gender.

The study included 62 patients, 30 (48.4%) females and 32
Complications occurred in 32 patients with 19 having
(51.6%) males with an average age of 36.95±19.1 years
major complications which required prolonged hospital
(Range: 9-81 years) and a mean follow up of 32.71±36.43
stay or readmissions, a second invasive intervention or a
months (Range: 1-124 months). Regarding the nature of
change in patient's functional status, while 13 patients
the tumour, 16 (25.4%) were benign while 29(47%) were
had minor complications that required non-operative
malignant primary tumours, whereas, 17(27.4%) cases
intervention without any change in functional status of
were of metastatic bone disease. Considering the
presentation of the disease, 6(9.7%)
were recurrence of the tumour while
4(6.5%) were residual disease after
marginal excision elsewhere. The
remaining 52 (84.4%) cases belonged
to the initial presentation group. The
most frequent sites were proximal
and distal femur, while there were 9
(15.3%) cases of proximal tibia and
5(8.5%) of proximal humerus.
Regarding the nature of surgery, 53
(85%) cases had primary surgery
while 9(15%) were undergoing
revision of a failed implant. In terms
of implant type, 30 (48.4%) patients
underwent distal femur mega endoprosthesis, 22(35.5%) had proximal
femur replacement with hip
Figure-1: Types of post-surgery major complications. DVT: Deep Vein Thrombosis
J Pak Med Assoc (Suppl. 5)
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Custom built prosthesis were introduced
in 1949 initially by Stanmore, however,
they gained popularity in 1970s because
of the advent of neo-adjuvant
chemotherapy and advancements in
diagnostic modalities. Over the next
decade, introduction of modular
prosthesis ensured not only the easy
availability and cheaper cost but also
more flexibility during resection.7
Moreover, though these implants have
been introduced primarily for oncological
indications but they have also been of
paramount utilization in the event of
revision surgeries with large osseous
defects, aseptic loosening, peri-prosthetic
fractures and pseudo-arthrosis.9

Figure-2: Survival curve of patients with regard to nature of tumor.

the patients. Major complications included deep
infections, dislocation, aseptic loosening, soft tissue
failure, neurovascular damage and local recurrence
(Figure-1). For management of complications, 6 required
open or closed reduction, 6 had wound debridement with
4 of them requiring additional flap coverage. Three
patients needed revision surgery while three more ended
up having amputation. One patient required tendon
transfers for radial nerve injury (Table-1).
Out of the 62 patients, 17 expired thus the survival rate
was 69.8%. Mean survival time was 76.3 months with
standard error of 8.55. Survival rate of primary malignant
bone tumours was 80% (Figure-2).

Discussion
The mean MSTS score was 72.09% and 52% patients had
some complications in the presented study. A major
complication was seen in 31% patients requiring a second
invasive intervention or lead to a change in functional
status. These included wound dehiscence, deep tissue
infection, major neurovascular damage, aseptic loosening
or dislocation. Minor complications as delayed wound
healing, cellulitis and superficial infection requiring
antibiotics therapy was encountered in 21% patients. Our
mean functional score was comparable to our previous
study.2 However, it remained lower than Tan et al. and
Tunn et al. which were 78% and 77% respectively.7,8

These custom prosthesis used to replace
the femur, the hip joint, part of the pelvis,
the knee joint, the humerus and shoulder
joint, and parts of the ulna and radius
which are the most common predilection
sites of primary bone tumours.10 In
addition to these, custom and modular
implants have also been involved in management of
metastatic bone disease particularly in the setting of a
pathological fracture and wherever the intent is
palliative.11,12 The most usual site, in case of metastatic
disease, has been proximal femur.12
Mega-prosthetic reconstruction has many advantages.
The load-bearing characteristics of prosthetic
reconstruction surgery offer immediate postoperative
stability and facilitate rapid rehabilitation. However,
appropriate patient selection is paramount to obtain
better and more consistent results. The involvement of
major structures is considered an important factor in
determination of limb salvage vs amputation. The
decision is to be made once patients are re-evaluated
after the neo-adjuvant treatment, through which, some
patients who are not candidates of limb salvage initially,
may experience shrinkage in tumour size and thus
increase in chances of limb salvage. Another patient
group is the one with poor prognostic factors like
metastasis on presentation, bone metastatic disease and
ineffective response to chemotherapy. Mega endoprosthetic reconstruction is a viable option in such
patients to improve quality of life when compared to
debilitating radical management, wherever there is a
limited life expectancy.13
Endo-prosthetic reconstruction has now comparable
results with amputation regarding oncological outcome
Vol. 71, No. 8 (Suppl. 5), August 2021

S-48

34th International Pak OrthoCon Conference 2021

Table-2: Comparison of our surgical and functional outcomes with international literature.
Author

Qadir et. al.2
Malawer et. al.6
Tan et. al.7
Natarajan et. al.16
Futani et al.26
Current Series

No. of
cases

Type of
prosthesis

MSTS
(%)

Aseptic Loosening /
Dislocation (%)

Implant
fracture (%)

Infection
(%)

16
68
19
17
22
62

Mix
Mix
Mix
Total Femur
Distal Femur
Mix

72.3
75
78.3
66.6
74
72.1

12.5
17
10.5
11.8
22.7
4.9

0
0
0
0
9.1
0

12.5
13
31.5
11.8
27.3
9.6

Figure-3A: Patient developed deep infection and wound dehiscence. Flap coverage
was attempted twice which failed.

Figure-3B: X-ray showing inadequate cement mantle causing aseptic loosening.

and long-term survival but also with better functional
outcome in terms of Musculoskeletal Tumour Society
(MSTS) score. Since, bone sarcomas are the fourth most
common cancer in individuals under the age of 25, this
demands longevity of the reconstructions. Furthermore,
cancer patients are more prone to complications, due to
the impaired immune system, longer surgery time, and
greater loss of tissue and structures.14 These megaprosthesis also have worse long-term results compared to
conventional total joint replacements.15

outcomes, deep infection and concomitant pathology
e.g., advanced osteoarthritis or AVN of ipsilateral joints
also has an influence.15,16 Comparison with other studies
in literature is displayed in Table-2.

Nevertheless, all of these studies were based on primary
bone tumours while our work also incorporated the cases
of metastatic bone disease. In terms of functional
J Pak Med Assoc (Suppl. 5)

On comparison with other studies17-19 with the rates of 4% to
30%, 9.6% of our patients showed peri-prosthetic infection
which is one of the most common complication after mega
endo-prosthesis apart from local recurrence (Figure-3A). This
is attributed to various risk factors like tumour disease,
chemotherapy-induced immunosuppression, poor soft
tissue situation due to radiation therapy, long operation time
and inadequacy of coverage.20 One patient with
metastatic renal carcinoma underwent tumour debulking

S-49
and proximal femur replacement while four with primary
malignant bone tumours received neo-adjuvant as well as
adjuvant chemotherapy. Another case was that of a 14
year old girl with Ewing's Sarcoma who developed periprosthetic infection after 5 years of index surgery, though
in literature, majority of the cases present within first two
years.20 No significant difference was found in the
infection rate between hip and knee surgeries. Recent
studies have shown the promising results of silver coated
mega-endoprosthesis in terms of decreased infection
rate, however, no long-term level 1 data is available yet.
Moreover, cost and availability have also been major
deterrents of those implants in our setting.21,22
Three amputations had been observed in our study in
which 2 of them had infection and patients underwent
multiple wound debridement and coverage. In the third
case, however, there was recurrence after undergoing
intramedullary nailing of the pathological fracture of
femur secondary to a Leiomyosarcoma, which was found
out on subsequent biopsy. Our overall limb salvage rate
was 95%.
Among the patients who required revision surgery, we
performed revision of femoral components only. Both
remained disease free, however, one of them developed
coronal instability after 10 years of initial surgery (Figure3B). One of the rare complications and cause of revision is
failure of hinge mechanism, which was also experienced
by one of our patients. He eventually developed knee
dislocation. Polyethylene (PE) bushing failure had been
the likely mechanism in our case, which is also reported as
one of the reasons of this type of failure.23
Our recurrence rate in primary malignancies remained 9%
which is comparable with literature. Both Ham et al. and
Malawer et al. reported 6% rate of local recurrence.6, 24
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important one was the small sample size despite a long
span of 10 years. This is because of the financial
limitations of our patient group. Secondly, we used
prosthesis from different providers, which may have a
bearing upon mechanical complications and long-term
survival of the implants. However, it had no bearing upon
resection plan and margins. Moreover, the follow up is too
short in some cases to have any implications upon
recurrence rate, functional score and particularly survival.

Recommendations
Future refinements in technique and technology would
certainly improve the outcome and minimize the
complications associated with limb salvage.
Disclaimer: None.
Conflict of Interest: None.
Funding Disclosure: None.
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